Welcome to our dedicated page for Nanalysis Sci news (Ticker: NSCIF), a resource for investors and traders seeking the latest updates and insights on Nanalysis Sci stock.
Nanalysis Scientific Corp. reports developments tied to portable Nuclear Magnetic Resonance spectrometers, MRI and imaging technology, and related services for industrial and research applications. Company updates describe instruments used in pharmaceutical, biotech, energy, food, materials, security, academic, and government settings, as well as a services division that maintains Nanalysis products and third-party imaging equipment.
Recurring news themes include quarterly and annual results, conference-call announcements, supply-chain and market-diversification updates, non-dilutive funding, private placement financings, equity incentive grants, and board composition changes. The company also references its long-term Canadian Air Transport Security Authority relationship for security-scanner maintenance at Canadian airports.
Summary not available.
Nanalysis Scientific Corp. (OTCQX:NSCIF, TSXV:NSCI) will be presenting at NobleCon18 on April 22, 2022, at 12:30 PM ET in Hollywood, Florida. CEO Sean Krakiwsky will also hold breakout sessions on April 20 and April 21 at various times. The presentation will be available via a high-definition video webcast the following day, accessible through Noble Capital Markets' website and Channelchek. Nanalysis specializes in portable Nuclear Magnetic Resonance (NMR) devices and aims to expand its market reach in multiple industries.
Nanalysis Scientific Corp. has secured $4,985,000 from the Canadian government to enhance its manufacturing operations and expand into global markets for nuclear magnetic resonance products. This funding, provided through Prairies Economic Development Canada, will be accessed over three years with interest-free repayments starting on September 1, 2025. The CEO, Sean Krakiwsky, expressed gratitude for this support, indicating it will help drive growth and innovation while mitigating supply chain risks. The Company focuses on developing portable NMR spectrometers for various industries.
Nanalysis Scientific Corp. announced a significant equity investment in Quad Systems AG, acquiring a 43% ownership stake along with an option to purchase the remaining shares. The company provided a CHF 1,000,000 convertible loan to Quad Systems and subscribed for shares totaling CHF 6,500,000. This investment is expected to enhance product offerings and support business growth. Nanalysis will appoint two representatives to Quad Systems' Board of Directors and has rights for future offers until July 1, 2023.
Nanalysis Scientific Corp. (OTCQX:NSCIF) announced the granting of 620,000 stock options to directors and officers at an exercise price of $1.32 per share, valid for five years. The options will vest in three stages: one-third after 12, 24, and 36 months. This strategic move aims to incentivize leadership and align their interests with shareholders.
Summary not available.
Nanalysis Scientific Corp. (NSCIF) released a corporate update on February 17, 2022, highlighting solid growth through 2021. The company reported annual revenues of approximately $16 million, a 103% increase year-over-year, and maintains gross margins of 63% to 65%. Key developments include the acquisition of K'Prime and Quad Systems, funded by a successful $15.2 million equity offering. Nanalysis aims to integrate these acquisitions and expand its sales channels, with CEO Sean Krakiwsky expressing confidence in continued growth in 2022 and beyond.
Nanalysis Scientific Corp. has successfully closed a public offering of common shares, raising $15,224,700.70. The company issued a total of 11,212,500 shares at a price of $1.10 per share, which includes shares from an over-allotment option. Additionally, 2,628,137 shares were issued through a private placement for $2,890,950.70. The funds will support sales, marketing, R&D, and potential acquisitions. The shares issued through the private placement are subject to a four-month hold period. Final acceptance by the TSX Venture Exchange is pending.
Nanalysis Scientific Corp. will provide a corporate update on February 17, 2021, followed by a conference call hosted by CEO Sean Krakiwsky and CFO Luke Caplette at 5:00 PM ET. Investors can join the call by dialing 1-877-451-6152 or through a webcast. The call will be archived for 90 days. Nanalysis specializes in portable MRI and NMR machines used in healthcare and industrial applications, aiming to capitalize on its proprietary technologies. The company trades under the ticker symbols NSCI on TSXV and NSCIF on OTCQX.
Summary not available.